Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. (MET) – Form 4 insider transaction filed 20 June 2025
Independent director William E. Kennard reported an automatic acquisition of 562 common shares on 17 June 2025. The shares were credited at a reference price of $77.85 under the company’s non-management director compensation program and immediately deferred into the MetLife Deferred Compensation Plan for Non-Management Directors. No open-market cash outlay occurred.
Following the transaction, Kennard’s direct ownership stands at 43,606 common shares. He also retains 10 shares indirectly through the MetLife Policyholder Trust, bringing his total reported beneficial holding to 43,616 shares.
The filing carries code “A(1),” indicating an exempt award related to board fees rather than discretionary buying or selling. No derivative securities were involved, and there were no dispositions. The update is routine, modest in size (<0.001 % of shares outstanding), and does not affect MetLife’s capital structure or liquidity.
Key takeaways for investors
- Incremental increase in insider equity aligns director incentives with shareholders.
- Because the shares were part of standard board compensation, the filing does not signal strategic sentiment or anticipated operational developments.
- Beneficial ownership data remains well below any control threshold; governance dynamics unchanged.
MetLife, Inc. (MET) filed a Form 4 reporting routine insider activity by non-management director Carlos M. Gutierrez. On 06/17/2025, Gutierrez received 562 shares of common stock (transaction code A) at a stated price of $0, reflecting the company’s policy to pay a portion of director retainers in equity. Following the grant, the director now owns 23,851 shares directly and 18,807 shares indirectly through the Carlos M. Gutierrez Trust. No derivative securities were involved, and the filing contains no sales or dispositions.
MetLife, Inc. (MET) – Form 4 insider transaction
Director Carla A. Harris disclosed the acquisition of 562 MetLife common shares on 17 Jun 2025. The reference price reported was $77.85, implying a transaction value of roughly $43.7 thousand. The shares stem from the company’s normal non-management director compensation program and were deferred through the MetLife Deferred Compensation Plan for Non-Management Directors. Post-transaction ownership equals 8,484 directly held shares. No derivative positions were created or exercised, and no shares were sold. The filing appears routine and compensation-related, with limited impact on overall share float or corporate governance.
Form 4 highlights
On 06/17/2025, MetLife, Inc. (MET) filed a Form 4 disclosing that non-management director Laura J. Hay acquired 562 shares of common stock at an implied transaction price of $77.85 per share. The stock represents the portion of the regular board retainer that is paid in equity; the director chose to defer receipt through the company’s Deferred Compensation Plan for Non-Management Directors.
Following the issuance, Hay’s direct beneficial holdings increased to 3,701 shares. No shares were sold and no derivative positions were created or exercised. The filing contains no other transactions or amendments, and there are no indications of a Rule 10b5-1 trading plan.
Given MetLife’s market capitalization and share count, the transaction is immaterial from a valuation standpoint and is considered routine insider compensation rather than an open-market purchase. It nevertheless confirms continued equity alignment between the board and shareholders.
MetLife, Inc. (NYSE: MET) filed a Form 8-K to report the results of its June 17, 2025 annual meeting of common shareholders. Three routine governance items were submitted and all received majority support.
- Board elections: Shareholders re-elected all eleven directors for terms expiring at the 2026 annual meeting. Support levels ranged from 97.8 % for Christian Mumenthaler to 94.4 % for Denise M. Morrison. Total broker non-votes on director items were 41.7 million.
- Auditor ratification: Deloitte & Touche LLP was re-appointed as independent auditor for 2025, receiving 558.7 million “For” votes (approx. 93 %), with 38.9 million against and 0.5 million abstentions.
- Say-on-Pay (advisory): Compensation for named executive officers was approved with 528.3 million “For” votes (approx. 95 %), 26.3 million against, and 1.9 million abstentions; 41.7 million broker non-votes applied.
No other business, financial results, or strategic transactions were disclosed. The filing is strictly limited to Item 5.07, indicating normal-course corporate governance actions rather than material operational developments.